scholarly journals Erratum: Schmidt H, Johansen JS, Gehl J, et al. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.Cancer. 2006;106(5):1130–9.

Cancer ◽  
2006 ◽  
Vol 107 (9) ◽  
pp. 2315-2315
Keyword(s):  
Prognostic Factor ◽  
Serum Level ◽  
Elevated Serum ◽  
Independent Prognostic Factor ◽  
Poor Survival ◽  
Elevated Serum Level

scholarly journals Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma

Cancer ◽  
2006 ◽  
Vol 106 (5) ◽  
pp. 1130-1139 ◽  
Author(s):  
Henrik Schmidt ◽  
Julia Sidenius Johansen ◽  
Julie Gehl ◽  
Poul F. Geertsen ◽  
Kirsten Fode ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Serum Level ◽  
Metastatic Melanoma ◽  
Elevated Serum ◽  
Independent Prognostic Factor ◽  
Poor Survival ◽  
Elevated Serum Level

Prognostic value of serum level of HER-2 extracellular domain (ECD) at diagnosis of HER-2 overexpressed primary breast cancer (BC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11508-e11508
Author(s):  
S. Thureau ◽  
F. Clatot ◽  
J. Pillé ◽  
S. Laberge-Le-Couteulx ◽  
O. Rigal ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Serum Level ◽  
Prognostic Value ◽  
Hormone Receptors ◽  
Elevated Serum ◽  
Elevated Serum Level ◽  
Adverse Prognostic Factor ◽  
Metastatic Relapse ◽  
Her 2

e11508 Background: Serum level of HER2 ECD is an adverse prognostic factor in HER2 over-expressed metastatic BC. We analyzed the prognostic value of serum level of HER2 ECD at the diagnostic of HER2 over-expressed primary BC. Methods: Patients with HER2 over-expressed primary BC treated with adjuvant trastuzumab in 2005 and 2006 were retrospectively analyzed. Serum level of HER2 ECD was assessed on frozen sera collected for CA15–3 measurement before initial treatment. Serum level of HER2 ECD was measured with an Elisa commercial kit (Oncogene Science, Cambridge, MA). The cut-off was 15μg/l as recommended. Results: Pre-treatment serum was available for 65 patients treated for non metastatic HER2 over-expressed BC. Seven patients (11%) had initially an elevated serum level of HER2 ECD (mean 25μg/l, range 15.1–38.9). After an average follow-up of 30 months, 4 patients (57%) out of the 7 with initially elevated serum level of HER2 ECD had a metastatic relapse of BC. In contrast, only 3 patients (5%) out of 58 with initially low serum level of HER2 ECD experienced relapse (p=0.004). Median of serum level of HER2 ECD was 17μg/l in patients who experienced relapse during follow-up whereas it was 8.4μg/l in patients who remained relapse-free (p=0.03). Univariate analysis showed that only elevated serum level of HER2 ECD and absence of hormone receptors expression were linked with metastatic relapse (p=0.0004 and p=0.02, respectively). Multivariate analysis showed that elevated serum level of HER2 ECD and absence of hormone receptors expression were linked with metastatic relapse (p=0.02 and p=0.04, respectively). Survival curves showed also that elevated serum level of HER2 ECD was related with a worse disease-free survival (p=0.0004). Conclusions: In this small series, elevated serum level of HER2 ECD was an adverse prognostic factor for HER2 over- expressed non metastatic primary BC. It was also a predictive factor for early failure of adjuvant treatment with trastuzumab. No significant financial relationships to disclose.

Elevated Serum Level of IL-23 Correlates with Expression of VEGF in Human Colorectal Carcinoma

2010 ◽  
Vol 41 (3) ◽  
pp. 182-189 ◽  
Author(s):  
Biljana Ljujic ◽  
Gordana Radosavljevic ◽  
Ivan Jovanovic ◽  
Sladjana Pavlovic ◽  
Nemanja Zdravkovic ◽  
...  
Keyword(s):  
Serum Level ◽  
Colorectal Carcinoma ◽  
Elevated Serum ◽  
Elevated Serum Level ◽  
Human Colorectal Carcinoma

scholarly journals Elevated Serum Level of Interleukin 17 in a Population With Prehypertension

2015 ◽  
Vol 17 (10) ◽  
pp. 770-774 ◽  
Author(s):  
Wei Yao ◽  
Yuemin Sun ◽  
Xuechun Wang ◽  
Kaijun Niu
Keyword(s):  
Serum Level ◽  
Elevated Serum ◽  
Interleukin 17 ◽  
Elevated Serum Level

Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients

2019 ◽  
Vol 40 (5) ◽  
pp. 555-563
Author(s):  
Soheil Tahani ◽  
Leila Dehghani ◽  
Hamidreza Jahanbani-Ardakani ◽  
Vahid Shaygannejad ◽  
Ali Fazli ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Serum Level ◽  
Neuromyelitis Optica ◽  
Elevated Serum ◽  
Elevated Serum Level ◽  
Multiple Sclerosis Patients

Elevated serum level of interleukin-10 in patients with systemic sclerosis

1997 ◽  
Vol 16 (6) ◽  
pp. 638-639 ◽  
Author(s):  
E. J. Kucharz ◽  
L. Brzezinska-Wcislo ◽  
A. Kotulska ◽  
W. Gasiorowska-Kielkowska ◽  
J. Gozdzik
Keyword(s):  
Systemic Sclerosis ◽  
Serum Level ◽  
Elevated Serum ◽  
Interleukin 10 ◽  
Elevated Serum Level
Sign in / Sign up

Export Citation Format

Share Document